Login / Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Clone
- EH12.2H7 (See other available formats)
- Regulatory Status
- RUO
- Other Names
- PD-1
- Isotype
- Mouse IgG1, κ
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
Anti-human PD-1 inhibits the binding of PD-L1. Immobilized PD-1-Fc was pre-incubated with increasing concentrations of anti-human PD-1 (clone EH12.2H7, purple squares) or isotype control (clone MOPC-21, purple circles), followed by incubation with a fixed concentration of PD-L1-Fc (1 µg/mL). Clone EH12.2H7 inhibits PD-1/PD-L1 interaction in a dose dependent manner.
Select size of product is eligible for a 40% discount! Promotion valid until September 30, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.
Product DetailsProduct Details
- Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Formulation
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
- Preparation
- The GoInVivo™ antibody was purified by affinity chromatography.
- Concentration
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This GoInVivo™ solution contains no preservative; handle under aseptic conditions.
- Application
-
FC - Quality tested
Block, IHC - Reported in the literature, not verified in house - Recommended Usage
-
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
For in vivo and in vitro applications, we recommend to perform a pilot experiment to determine the optimal concentration to use for each particular experiment. - Application Notes
-
GoInVivo™ products are guaranteed to be pathogen-free based on the IDEXX BioResearch IMPACT test via PCR. For a full listing of pathogens tested, visit the GoInVivo™ Webpage.
Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3 and immunohistochemical staining of paraformaldehyde fixed frozen sections13. -
Application References
(PubMed link indicates BioLegend citation) -
- Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
- Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
- Velu V, et al. 2007. J. Virol. 81:5819. (FA)
- Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
- Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
- Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
- Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
- Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
- Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
- Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
- Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
- Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
- Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
- Product Citations
- RRID
-
AB_2566290 (BioLegend Cat. No. 329946)
AB_2566291 (BioLegend Cat. No. 329947)
AB_2566292 (BioLegend Cat. No. 329948)
AB_2565904 (BioLegend Cat. No. 329943)
AB_2566078 (BioLegend Cat. No. 329944)
AB_2566079 (BioLegend Cat. No. 329945)
Antigen Details
- Structure
- Immunoglobulin superfamily
- Distribution
-
Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells
- Ligand/Receptor
- B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
- Cell Type
- B cells, T cells, Thymocytes, Tregs
- Biology Area
- Cancer Biomarkers, Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Gene ID
- 5133 View all products for this Gene ID
- UniProt
- View information about CD279 on UniProt.org
Related Pages & Pathways
Pathways
Customers Also Purchased
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
Follow Us